Insulin resistance precedes and predicts the onset of type 2 diabetes mellitus (DM2), a chronic disease that causes high morbidity and mortality worldwide. In affected people, insulin is unable to ...

In 2021, a research team discovered the insulin-inhibitory receptor 'Inceptor' and its role as a suppressor of the insulin signaling pathway. Now, the researchers have unlocked another, even more ...

A large proportion of people living with type 2 diabetes treated with basal insulin therapy remain inadequately controlled ...

Research targeting the insulin-inhibitory receptor, or inceptor, unveils promising avenues for beta cell protection, offering hope for causal diabetes therapy. These findings, led by Helmholtz Munich ...

Developing resistance to insulin is a key step on the road to diabetes, making insulin resistance a target for treating metabolic dysfunction. Insulin orchestrates blood glucose levels by signaling ...

A team led by Novo Nordisk’s Rita Slaaby developed the glucose-responsive insulin, which is called NNC2215. The insulin in NNC2215 makes links to two moieties: a glucose-binding macrocycle and a ...

Three years ago, the inceptor protein was discovered and its role as an inhibitor of the insulin signaling pathway was described. Inceptor and the insulin receptor are located on the surface of beta ...

Adrenomedullin disrupts insulin signaling in blood vessels, leading to systemic insulin resistance in obesity-associated type 2 diabetes, according to a new study by a team at the Max Planck Institute ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity. GLP-1 receptor ...